摘要
目的 :观察通心络胶囊对不稳定型心绞痛 (UAP)的临床疗效及其不良反应 ,用血清心肌肌钙蛋白 T(c Tn T)含量判断 UAP预后。方法 :对 2 3例不稳定型心绞痛患者进行内科强化治疗 ,与强化治疗加通心络干预治疗组 (2 3例 )比较 ,并测定血清 c Tn T、心肌酶谱〔如肌酸激酶及其同工酶 (CK及 CK MB)〕浓度 ,观察住院期间心血管事件的发生率。结果 :服用通心络组心绞痛积分为 (2 .72± 1.85 ) m V· min,明显低于内科常规治疗组〔(3.76± 2 .5 5 ) m V· min,P<0 .0 1)〕。不稳定型心绞痛患者中 c Tn T≥ 0 .2μg/L的心血管事件发生率明显高于c Tn T正常者 (33.3%比 5 .0 % ,P<0 .0 1) ,c Tn T的阴性预期值达 95 %。结论 :通心络胶囊是治疗 U AP的安全有效药物。 c Tn T可用于判断 U
Objective:To observe the clinical curative effect and side effect of Tongxinluo capsule(通心络胶囊) on treating unstable angina pectoris(UAP).Methods:Serum cardiac troponin T(cTnT),creatine kinase (CK) and isoenzyme MB (CKMB) were simultaneously measured in 46 patients with UAP.Serum cTnT,a specific marker reflecting myocardial injury was detected by immunoassay.Results:The accumulating scores points of angina pectoris in Tongxinluo group were lower significantly than that in conventional treatment group〔(2 72±1 85)mV·min vs.(3 76±2 55)mV·min,respectively, P <0 01〕.Among the 46 patients,the incidences of cardiac events,including acute myocardial infarction,sudden cardiac death and interventional treatment,were significantly higher in group of cTnT ≥0 2 μg/L than those in group of cTnT<0 1 μg/L (33 3% vs.5 0%, P <0 01).The negative predictive value was 95%.Conclusions:Tongxinluo capsule is a safe and effective medicine in treatment for UAP.The serum cTnT level can predict the prognosis of patients with UAP.
出处
《中国中西医结合急救杂志》
CAS
2000年第5期270-272,共3页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
基金
江苏省科技指导性计划项目 !(No.BS98381)
关键词
心绞痛
通心络胶囊
肌钙蛋白
预后
中医药疗法
unstable angina pectoris
Tongxinluo capsule
troponin
prognosis
traditional Chinese medicine
